Veru Inc. Announce Positive Topline Safety Data from Phase 2b QUALITY Study of Enobosarm Combined with Semaglutide

Veru Inc. announced positive topline safety data from its Phase 2b clinical study evaluating enobosarm combined with semaglutide for weight management in older patients, showing a favorable safety profile with fewer gastrointestinal side effects compared to semaglutide alone. The study also demonstrated significant fat loss while preserving lean mass, leading Veru to propose the 3mg dosage for its Phase 3 program and request an FDA meeting to discuss regulatory paths forward. Topline efficacy data for an extension study examining enobosarm monotherapy in preventing weight regain after discontinuing semaglutide is expected soon.

Analysis

Veru Inc. has reported positive topline safety and efficacy data from its Phase 2b QUALITY clinical study, evaluating enobosarm in combination with semaglutide for weight management in older patients. The enobosarm 3mg dose, proposed for the Phase 3 program, demonstrated a favorable safety profile, notably reducing specific gastrointestinal side effects such as nausea (11% with enobosarm 3mg + semaglutide vs. 20% with placebo + semaglutide) and Gastroesophageal Reflux Disease (5% vs. 13%), compared to semaglutide alone. Efficaciously, the enobosarm 3mg plus semaglutide combination resulted in 99.1% of total weight lost being attributable to fat mass, alongside a 99.1% mean relative reduction in loss of lean mass (p <0.001 versus placebo + semaglutide). Furthermore, this combination led to a 62.4% relative reduction in patients experiencing a decline of 10% or more in stair climb power (p=0.0066), indicating preserved physical function. Veru has requested an End of Phase 2 meeting with the FDA, anticipated in Q3 2025, to discuss the Phase 3 clinical program design, which is proposed to be similar to the Phase 2b study. Topline efficacy and safety results from an extension study assessing enobosarm monotherapy for preventing fat and weight regain following discontinuation of semaglutide are expected in the second quarter of 2025. Additionally, a novel modified-release oral formulation of enobosarm is under development, targeting availability for Phase 3 studies and potential patent protection until 2045. While these results are encouraging, it's noted that one subject on the 3mg enobosarm dose experienced a transient, mild increase in alanine aminotransferase (ALT) that resolved while on treatment; the 6mg dose showed a higher incidence of ALT elevation (11%). Insider activity includes purchases of 150,000 shares by an executive in the last six months, whereas recent institutional holdings data from Q1 2025 and Q4 2024 show significant divestitures by funds such as Perceptive Advisors (removed 6.48 million shares) and Millennium Management (removed 3.75 million shares), contrasted with substantial new or increased positions by others like MPM Bioimpact (added 2.31 million shares) and UBS Group AG (added 1.52 million shares), suggesting a mixed but dynamic institutional outlook.

Key Decisions for Investors

• Investors should view the positive Phase 2b data for enobosarm as a significant clinical milestone for Veru, potentially addressing key limitations of GLP-1 agonist therapy such as muscle loss and gastrointestinal tolerability, though progression through Phase 3 and regulatory approval remain critical upcoming challenges.
• Key near-term catalysts to monitor include the topline results from the Phase 2b extension maintenance study, expected in Q2 2025, and the outcome of the End of Phase 2 meeting with the FDA, anticipated in Q3 2025, both of which could materially influence the company's valuation and strategic direction.
• The divergent institutional investment activity, characterized by substantial sales from some large funds alongside significant new investments from others and supportive insider buying, necessitates careful due diligence regarding fund-specific theses and a thorough assessment of Veru's risk-reward profile before committing capital.